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INTRODUCTION 
“The liveliest—literally—field of 3D printing may sound like something 
from a sci-fi movie, but (spoilers) it’s real and happening now.”1 Indeed, this 
new field is “nothing less than the start of a new industrial revolution,”2 and 
3D printing promises to be a “disruptive” force in the market.3 This spring, 
Boeing passed Federal Aviation Administration safety tests for the first 
printed structural components for a plane.4 The plane manufacturer will start 
using 3D-printed parts in its engines, which will yield faster manufacturing 
processes and billions of dollars in savings.5 
The potential applications of this new technology are endless. Industry 
leaders and world leaders alike recognize and are excited by this opportunity. 
As then–President Obama said, “3D printing has the potential to revolutionize 
the way we make almost everything.”6 
 
1 Arif Sirinterlikci & Lauren Walk, Bioprinting: Science or Fiction?, MANUFACTURING 
ENGINEERING 51 (2014). 
2 How 3D Printing Will Reshape the World, CNN, http://edition.cnn.com/TECH/specials/make-
create-innovate/3d-printing/ [https://perma.cc/BR8L-M6N3]. 
3 See, e.g., Rebecca Neu, 3D Printing: A Revolutionary Advance for the Field of Urology?, TECH. 
INNOVATION MGMT. REV., Mar. 2014, 19, 19 (foreshadowing 3D printing as “one of the top ten 
most disruptive technologies of the coming decade”); Andrew Tsai & Chinh H. Pham, Fast Forward: 
Even Companies That Don’t Embrace 3D Printing Will Need to Weigh Risks 24 CORPORATE COUNSEL 
25 (2017) (“3D printing technology has become truly disruptive to a wide range of industries and 
businesses.”). 
4 Mariella Moon, Boeing Uses First FAA-Approved 3D-Printed Parts for the 787, ENGADGET 
(Apr. 11, 2017), https://www.engadget.com/2017/04/11/boeing-faa-approved-3d-printed-metals-787/ 
[http://perma.cc/9V5Y-L8XT]. 
5 Id. 
6 President Barack Obama, 2013 State of the Union Address (Feb. 12, 2013). 
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One of the applications that holds incredible promise is 3D printing in 
the medical context, which includes the possibility of 3D-printed organs for 
humans.7 There will come a time in the not-so-distant future when our 
children or grandchildren will balk at the notion that, just a generation ago, 
people died because their doctors could not locate an organ—or only one with 
high risks of rejection—to complete the transplant. According to health care 
technology expert Tom Todorow, the introduction of 3D-printed organs into 
the medical landscape is a relative certainty; not a question of if, but when.8 
Root Analysis, a medical technology consulting company, anticipates that it 
should be possible to print kidneys in six years, with livers to follow soon 
after.9 The prospect of printed organs necessitates the following question: is 
the market ready for 3D-printed organs? The answer, with some reservations 
about the ethical challenges ahead, is yes: the regulatory regime as it currently 
stands can handle 3D-printed organs. 
Before delving into the questions surrounding 3D printing in the medical 
field specifically, the U.S. organ shortage crisis warrants attention. On 
average, twenty-two people die every day while awaiting an organ 
transplant.10 The waitlist for organs is over 116,000 people long and, every 10 
minutes, someone new is added.11 Over the last 5 years, the number of organ 
transplants has increased by 20 percent, hitting a new record of over 33,500 
transplants in 2016.12 The organ supply will not catch up with the current 
demand without some assistance from another source—such as printers that 
can manufacture organs. 
The implications of pervasive implementation of 3D printing with 
biological material, also known as “bioprinting,” are vast. They present 
never-before-seen hurdles, which are particularly complicated due to the 
vulnerability of the patients, who often need new organs to survive, involved. 
In this Comment, I limit the scope of this inquiry to the most immediate 
challenges of embracing 3D-printed organs in our health care market: potential 
statutory roadblocks, regulatory concerns over manufactured organs, and 
ethical challenges of which we must remain aware. I submit one path by which 
3D-printed organs can fit in our current legal and regulatory framework. I 
 
7 See Neu, supra note 3, at 21-22 (“Considering the social and financial costs of current therapy 
options, the technology of 3D [organ] printing holds promise for not only providing a superior 
quality of life for suffering patients but also reducing the long-term costs of care.”). 
8 Interview with Tom Todorow, Chief Fin. Officer, Children’s Hosp. of Phila. (Mar. 30, 2017). 
9 A Tissue of Truths—Printed Human Body Parts Could Soon be Available for Transplant, 
ECONOMIST (Jan. 28, 2017), http://www.economist.com/news/science-and-technology/21715638-
how-build-organs-scratch [https://perma.cc/BWG8-PZW9] [hereinafter A Tissue of Truths]. 
10 Organ Procurement and Transplantation Network, U.S. DEP’T HEALTH & HUM. SERVS., 
https://optn.transplant.hrsa.gov [https://perma.cc/724N-J86S]. 
11 Id. 
12 Id. 
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also define who should be charged with regulating them and propose how 
future regulators should do so. Finally, I raise additional concerns of 3D-printed 
organs that will require deeper analysis as more information becomes available, 
including the myriad ethical challenges presented by this new technology. 
The U.S. Food and Drug Administration (FDA) is the appropriate body 
to regulate 3D-printed organs because a manufactured organ must be treated 
differently than a human organ, which can be transplanted as “simply” part 
of the practice of medicine. It remains to be seen how the FDA will gather 
sufficient data to satisfy premarket approval requirements, determine who 
gets access and when, and how to govern the marketing of 3D-printed organs 
because the output is individualized. But the process by which the organs are 
created can be scaled dramatically. In so doing, those in charge must also 
confront unique, multifaceted ethical challenges. 
I. WHAT IS 3D PRINTING AND WHO CARES? 
A. The History and Mechanics of 3D Printing 
The concept of 3D printing has existed for decades, but industries, 
scientists, and engineers only recently started to appreciate its full potential. 
Chuck Hull, an American inventor with a background in engineering and 
physics, created the concept of 3D printing back in the 1980s, yet he was only 
just formally recognized for this accomplishment.13 
Three-dimensional outputs from a 3D printer are created, in some ways, 
by similar means as a conventional two-dimensional printer. Instead of the 
two-dimensional layer of ink traditionally seen on a printed page, the 3D 
printer puts billions of layers of whatever material composes the “ink” on top 
of one another to create the object.14 Together, they form the output that the 
printer was instructed to create. 
3D printing is also sometimes called “additive manufacturing,” in reference 
to the “additive” process by which the printer creates its three-dimensional 
output. Rather than moving across a piece of paper to place a single layer of 
ink dots, the 3D printer goes back and forth many more times, “laying down 
successive layers of materials” from computer-aided design (CAD) files that 
 
13 See Sam Davies, 3D Printing Inventor Chuck Hull Accepts Nomination as Winner of 2017 
Washington Award, TCT MAG. (Feb. 21, 2017), http://www.tctmagazine.com/3D-printing-news/3d-
printing-inventor-chuck-hull-winner-washington-award/ [https://perma.cc/ABY2-NGQJ] (receiving 
the Western Society of Engineers’ Washington Award, presented to an engineer “whose innovation 
and accomplishments have had a positive impact on humankind”). 
14 See Tsai & Pham, supra note 3 (defining 3D printing as “the laying down of successive layers 
of materials”). 
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the physicians and engineers worked together to create.15 These printers do 
not use conventional printer ink, but rely on a variety of materials, 
“includ[ing] plastics, polymers, glass, metal, wax, edible goods and even 
human tissue.”16 
In the early 2000s, scientists “discovered that living cells could be sprayed 
through the nozzles of inkjet printers without damaging them.”17 Hull himself 
was surprised at how quickly it became apparent that this technology could, 
and was going to, revolutionize the medical field.18 
When bioprinting an organ, a patient’s own cells are used, rather than 
using synthetic materials. A commonly used method begins with a biopsy to 
remove some of a patient’s cells. The biopsied cells are subsequently subjected 
to a “growth medium to proliferate cell growth and multiplication and to form 
aggregate cells that are the base of ‘bioink.’”19 The “bioink” is then layered in 
the same way as described above. Sometimes an additive must be used to 
ensure that the bioink is printed in the right shape. This additive can be 
removed once the printing process is complete, at which point the “as-formed 
bioprinted tissue is left to grow”20 or it can be made of biocompatible 
material21 or can be biodegradable.22 Currently, researchers are working to 
determine how to print complicated and intricate bodies of blood vessels that 
will produce the necessary supply of blood and oxygen through a printed 
 
15 Id. 
16 Id. 
17 A Tissue of Truths, supra note 9; cf. Sam Fifer & Dimitry Kapmar, A Look at the Patentability 
Of 3-D Printed Human Organs, LAW360 (May 28, 2013, 12:58 PM), https://www.law360.com/
articles/439549/a-look-at-the-patentability-of-3-d-printed-human-organs [https://perma.cc/5YS4-
YCPJ] (drawing a parallel between bioprinting and the famous replicator from the Star Trek series). 
18 See Matthew Ponsford & Nick Glass, “The Night I Invented 3D Printing,” CNN (Feb. 14, 2014), 
http://www.cnn.com/2014/02/13/tech/innovation/the-night-i-invented-3d-printing-chuck-hall/ 
[https://perma.cc/2RVN-TN8A] (discussing in an interview about the success of 3D printing that 
he was surprised about “[s]ome of the medical applications,” and that “it became pretty clear that 
this was going to work”). 
19 Gabriela I. Coman, 3-D Bioprinting: 5 Things Medical Device Cos. Should Know, LAW360 (Feb. 
18, 2016, 10:53 AM), https://www.law360.com/articles/760558/3-d-bioprinting-5-things-medical-
device-cos-should-know [https://perma.cc/C7RG-TS6C]. 
20 Id. 
21 See Jenny Morber, Custom Organs, Printed to Order, PBS (Mar. 18, 2015), http://www.pbs.org/
wgbh/nova/next/body/3d-printed-organs [https://perma.cc/A84Z-2MZK] (discussing biomedical 
researcher Roger Narayan’s substitution of vitamin B12 as a biocompatible material for the toxic 
polymers typically used in 3D printing). 
22 Cf. Clare Scott, Wake Forest Researchers Successfully Implant Living, Functional 3D Printed 
Human Tissue into Animals, 3DPRINT.COM (Feb. 16, 2016), https://3dprint.com/119885/wake-
forest-3d-printed-tissue/ [https://perma.cc/8JJ3-BYFM] (describing the Integrated Tissue and 
Organ Printing System’s process, which is unique in its ability to print the cells and “scaffold” 
simultaneously). 
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organ and to the rest of a patient’s body.23 This is a significant barrier to 
market entry, but technological advances continue to provide hope.24 
While the application of bioprinting remains in its relatively nascent 
stages,25 the medical field currently utilizes other, less biologically-based 
applications in hospitals and for training purposes. 
Challenges of advancing 3D printing with biomaterials need not detract 
from the remarkable success 3D printing has already achieved in health care. 
Some 3D-printed products currently in use in the medical field include dental 
implants, tailored orthopedics and tools used in maxillofacial surgery.26 To be 
clear, the arguments I submit herein refer to the novel use of 3D printers to 
create biologically-based, synthetic organs. The manufacturing process itself 
is regulated separately and it is not covered in this Comment. By printing an 
exact replica of a specific human’s organ with synthetic materials, doctors can 
practice before performing operations on their patients.27 This opportunity 
benefits new medical students and the most experienced surgeons alike. 
Furthermore, some companies have successfully printed organic tissues,28 
which can be used for drug and cosmetic testing.29 The FDA has also 
 
23 See Coman, supra note 19 (“[B]ioprinting companies are still a few years away from a fully-
functioning printable organ such as the heart.”). 
24 See Jordan S. Miller, Department of Bioengineering Faculty Profile, RICE U., 
http://bioengineering.rice.edu/faculty/Jordan_Miller.aspx [https://perma.cc/QPS2-M87J] (noting 
that the potential for creating 3D-printed organs “is fundamentally limited by the lack of 
comprehensive vascularization strategy for engineered 3D tissues”); see also Katherine Harmon, A 
Sweet Solution for Replacing Organs, SCI. AM., Apr. 2013, at 55 (describing Miller’s method of using 
sugar molds of blood vessels, around which the 3D-printed organs can form and remodel). 
25 See A Tissue of Truths, supra note 8 (“As yet . . . ‘bioprinting’ remains largely experimental. 
But bioprinted tissue is already being sold for drug testing, and the first transplantable tissues are 
expected to be ready for use in a few years’ time.”). But see id. (describing work by researchers, who 
have successfully printed and implanted “ears, bones and muscles into animals, and watched these 
integrate properly with their hosts” and a Northwestern University group who “even printed 
working prosthetic ovaries for mice” through which “recipients were able to conceive”). 
26 A Vision for 3D Printing in Pharma Manufacturing, PHARMACEUTICAL TECH. (Sept. 29, 2016), 
http://www.pharmtech.com/vision-3d-printing-pharma-manufacturing [https://perma.cc/72U3-UGJS]. 
27 See, e.g., 3-D Printed Organs Help Houston Doctors Train for Complicated Surgeries, KTRK-TV 
(Dec. 14, 2016), http://abc13.com/health/3-d-printed-organs-give-surgeons-practice-runs/1657014/ 
[httpss://perma.cc/LHZ5-47D3] (reporting on a Houston doctor who was able to complete a 
complex kidney surgery in less than half an hour after practicing on a 3D-printed replica 
beforehand). 
28 See, e.g., BIOBOTS https://www.biobots.io [https://perma.cc/G9U8-PH22] (providing 
quotes from industry leaders praising their company’s desktop bioprinter for expanding accessibility 
of printing living tissue). 
29 See About Organovo, ORGANOVO, http://organovo.com/about/about-organovo/ [https://
perma.cc/XKM4-54G8] (outlining company’s mission to provide printed tissues that may replicate 
human tissue for the purposes of drug testing); A Tissue of Truths, supra note 8 (“L’Oréal already grows 
about five square met[er]s of skin a year using older and slower technology. Bioprinting will permit it 
to grow much more, and also allow different skin types and textures to be printed.”); JOHN BERGIN, 
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approved drugs30 and devices31 created with the help of 3D printing. While 
most drugs are not yet patient or sub-population specific on a large scale, the 
technology has allowed for the creation of “devices unique to . . . specific 
patient[s].”32 A recent example of this is FDA approval of Kymriah, a 
groundbreaking drug that “uses patients’ genetically altered immune cells to 
fight” leukemia in children and young adults.33 
Among those who understand the promise of 3D printing, it is rare to find 
someone capable of defining the limits of its potential. Hull himself points 
out that 3D printing’s “traditional limits,” which include “material properties, 
speed, [and] making millions of things” will likely be less limiting in the very 
near future.34 Likewise, industry expert Emil Ciurczak said “[t]he limits of 
3D printing are merely the needs and imagination of the researchers 
modelling the products of 3D [printing].”35 
B. The Market for 3D-Printed Organs 
Both the bioprinting community specifically and the pharmaceutical 
industry at large have taken great interest in the promise of 3D-printed organs. 
Startup companies committed to this area have emerged and survived, and 
American pharmaceutical giants such as Johnson & Johnson have taken 
notice.36 This comes as no surprise considering that experts estimate the value 
of the 3D bioprinting market alone to be in the hundreds of millions of dollars 
 
BIOPRINTING: TECHNOLOGIES AND GLOBAL MARKETS 39 (2016) (citing Proctor & Gamble and 
BASF as other cosmetics companies who have partnered with the bioprinting industry for testing). 
30 See, e.g., Hope King, First 3D-Printed Drug Approved by FDA, CNN (Aug. 4, 2015), 
http://money.cnn.com/2015/08/04/technology/fda-3d-printed-drug-epilepsy/ [https://perma.cc/L7NQ-
6YXZ] (discussing the approval of Spritam, a 3D-printed drug, for treatment of epilepsy patients). 
31 See Medical Applications of 3D Printing, U.S. FOOD & DRUG ADMIN. (Dec. 21, 2016), 
https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/3DPrintingofMedicalDevic
es/ucm500539.htm [https://perma.cc/4FZX-B5VC] (providing a list of commercially available 3D-
printed medical devices, including guides to assist with proper surgical placements, implants and 
external prostheses). 
32 Id. 
33 Laurie McGinley & Carolyn Johnson, FDA Clears First Gene-Altering Therapy—‘A Living 
Drug’—For Childhood Leukemia, WASH. POST (Aug. 30, 2017), https://www.washingtonpost.com/
news/to-your-health/wp/2017/08/30/fda-approves-first-of-its-kind-living-drug-for-childhood-
leukemia/?utm_term=.a4db592cc7b6 [https://perma.cc/V8US-9TTT]. 
34 Ponsford & Glass, supra note 18; see also Tsai & Pham, supra note 3 (describing the future of 
3D printing as “[e]verything and anything. Imagine waking up and printing yourself a breakfast 
with a customized nutritional profile based on your activity needs for the day.”). 
35 See supra note 26. 
36 See A Tissue of Truths, supra note 8 (“Johnson & Johnson . . . is so convinced that bioprinting 
will transform parts of medical practice that it has formed several alliances with interested academics 
and biotechnology firms.”). 
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already.37 Furthermore, the market is growing at an annual rate of 
approximately forty-four percent, which puts market value estimates in the 
billions within five years.38 
More broadly, twenty-six percent of manufacturing companies have 
already invested in 3D printing globally and that number is projected to climb 
to just under sixty percent by 2022.39 The health care sector could benefit 
from following the manufacturing sector’s example because productivity in 
the manufacturing sector has increased seventy-eight percent in the last 
fifteen years, while the health care sector has essentially remained stagnant at 
just six percent during that time.40 While the ramp up of public investment 
in 3D printing was slow at the onset—with just $300 million between 1987 
and 2010—the pace and volume have increased significantly since then, with 
$4 billion in public investment in the last five years and a projected $10 billion 
more by 2025.41 As a result, the value of the global 3D printing market is 
estimated to reach $22.8 billion by 2022, which is “much faster than expected.”42 
Industry reports note a list of important factors that currently act as 
“growth driving force[s]” for bioprinting, including the aging population, 
desire to move away from animal testing, clinical needs for wound care, and 
the continued improvement of the bioprinting field, among others.43 On a 
larger scale, 3D printing also promises to be a substantial money saver for 
many players.44 
With future economic projections in the billions, and industry giants from 
various sectors onboard, 3D printing is here to stay. The introduction of the 
viable and transplantable 3D-printed organ will come in our lifetime, backed 
by the world’s brightest minds and the global economy’s most formidable 
members. In the meantime, policymakers must construct a legal framework 
capable of supporting and regulating them upon their arrival. However, a 
preliminary hurdle remains between the economic and intellectual promise 
of 3D-printed organs and the construction of mechanisms to support their 
 
37 See BERGIN, supra note 29, at 7 (“The global bioprinting market is valued at an estimated 
$295 million in 2016.”). 
38 See id. (noting the “forecast value of $1.8 billion by 2021” for bioprinting globally). 
39 3D PRINTING MARKET OUTLOOK AND FORECASTS 2017–2022 22 (2016). 
40 Stephanie Carlton, Member of the Governing Board for the Health Care Cost Institute, 
Remarks at The Future of American Health Care Panel Hosted by Wharton Public Policy Initiative 
(May 1, 2017). 
41 See supra note 39, at 23. 
42 Id. at 26, 33. 
43 BERGIN, supra note 29, at 13. 
44 See supra note 39, at 25 (“GE wants to bring more than 1000 3D printing machines online in 
the next 10 years and gain cost savings of $3-$5 billion.”). 
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introduction: the National Organ Transplant Act of 1984 (NOTA),45 which, 
on its face, seems to proscribe paying for them as a federal crime.  
II. PAYING FOR 3D-PRINTED ORGANS IS “NOTA” FEDERAL CRIME 
NOTA prohibits “any person to knowingly acquire, receive, or otherwise 
transfer any human organ for valuable consideration for use in human 
transplantation if the transfer affects interstate commerce.”46 First, let us 
dispose of the reference to interstate commerce. It is without debate that the 
mere promise of 3D-printed organs has already proven to not only affect 
interstate commerce, but to also be a “disruptive” force in the U.S. economy.47 
Therefore, I stipulate that 3D-printed organs, insofar as their effect on 
interstate commerce, fall within the law’s scope. Instead, “human organ” and 
“valuable consideration” are the terms that distinguish 3D-printed organs 
from NOTA’s intended arena. 
A. 3D-Printed Organs are Not “Human Organs” 
NOTA defines “human organ” as “the human (including fetal) kidney, 
liver, heart, lung, pancreas, bone marrow, cornea, eye, bone, and skin or any 
subpart thereof and any other human organ (or any subpart thereof, including 
that derived from a fetus) specified by the Secretary of Health and Human 
Services by regulation.”48 According to the Dictionary Act, which defines 
important terms used in the United States Code, “human” (therein referred 
to as “human being”) makes reference to members of the homo sapiens 
species who are “born alive at any stage of development.”49 The 
corresponding regulations to NOTA also refer to organ donors as “human 
being[s],” consistent with the Dictionary Act.50 Therefore, human, as used in 
NOTA, must be the adjective meaning from a human being. 
If the Ninth Circuit serves as any indication, we can expect the courts will 
find no reason to construe the definition of organs differently, as it has 
confined the meaning to just the statutory text.51 If this narrow construction 
 
45 National Organ Transplant Act of 1984, 42 U.S.C. § 274e (2012). 
46 Id. 
47 See Tsai & Pham, supra note 3. 
48 42 U.S.C. § 274e(c)(1) (emphasis added). 
49 Dictionary Act, 1 U.S.C. § 8 (2012). 
50 Definitions, 42 C.F.R. § 121.2 (2013). 
51 See Flynn v. Holder, 684 F.3d 852, 864-65 (9th Cir. 2012) (“The statute does not prohibit 
compensation for donations of blood [or] . . . peripheral blood stem cells. The [HHS] Secretary has 
not exercised regulatory authority to define blood or peripheral blood stem cells as organs. We 
therefore need not decide whether prohibiting compensation for such donations would be 
unconstitutional.”). 
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persists, it seems likely that the courts would uphold compensation for other 
transplantations that fall outside the scope of the text itself. 
One of the most recent additions to the regulations’ defined organs, the 
vascularized composite allograft,52 comes closest to describing 3D-printed 
organs and tissues because they are “vascularized and require[] blood flow by 
surgical connection of blood vessels to function after transplantation; [and] 
contain[] multiple tissue types,”53 just as 3D-printed organs do. However, a 
vascularized composite allograft must specifically come “from a human donor 
as an anatomical/structural unit” and be “minimally manipulated (i.e., 
processing that does not alter the original relevant characteristics of the organ 
. . . ).”54 3D-printed organs are made solely from manipulated cells. As such, 
they clearly fail to conform with this definition.55 Accordingly, organs that are 
printed, rather than those that are harvested from a human being, should fall 
outside the scope of NOTA-defined organs. 
Moreover, even if 3D-printed organs do not fall outside the scope, the law 
itself unambiguously delegates power to Health and Human Services (HHS) 
to provide a regulatory definition of a human organ. As the agency that will 
be tasked with regulating 3D-printed organs, HHS regulators could resolve 
any doubt by explicitly defining 3D-printed organs for human transplantation 
as distinct from organs donated from other human donors. 
A law is more than words in a vacuum, and the legislative history and 
context in which NOTA was passed are relevant. NOTA became law with 
bipartisan support, including support from President Reagan.56 During the 
1970s and 80s, “medical science improvements and the related demand for 
transplant organs prompted governments to search for new ways to increase 
the supply of organs for donation.”57 In the congressional hearings about 
 
52 See generally HEALTH RESOURCES & SERVICES ADMIN., VASCULARIZED COMPOSITE 
ALLOGRAFT (VCA) TRANSPLANTATION COMM., IMPLEMENT THE OPTN’S OVERSIGHT OF 
VASCULARIZED COMPOSITE ALLOGRAFTS (VCAS) 4 https://optn.transplant.hrsa.gov/media/
1118/05_vca_implementation.pdf [http://perma.cc/ZZ29-W5VZ] (describing Vascularized 
Composite Allotransplantation (VCA) as “transplants composed of several different kinds of tissues 
(i.e., skin, muscle, bone), such as those in the hand, arm, or face, transferred from donor to recipient 
as a single functional unit”). 
53 §§ 121.2(1)–(2). 
54 §§ 121.2(3)–(5). 
55 See United States v. Regenerative Scis., LLC, 741 F.3d 1314, 1319 (D.C. Cir. 2014) 
(characterizing appellant’s “autologous stem cell procedure,” without FDA approval, as beyond the 
practice of medicine and subject to regulation by the Federal Food, Drug & Cosmetic Act); Frances 
H. Miller, New Wine in Old Bottles, FDA’s Role in Regulating New Technologies: Introduction, in FDA 
IN THE 21st CENTURY 434 (Holly Fernandez Lynch & I. Glenn Cohen eds., 2015) (discussing 
Regenerative Sciences in reference to the FDA’s role in regulating new technologies). 
56 Ronald Reagan: Statement on Signing the National Organ Transplant Act, AM. PRESIDENCY 
PROJECT, http://www.presidency.ucsb.edu/ws/?pid=39282 [https://perma.cc/3HY3-9YLK] (providing 
President Reagan’s remarks that accompanied his signing NOTA, a bipartisan effort, into law). 
57 Newman v. Sathyavaglswaran, 287 F.3d 786, 794 (9th Cir. 2002). 
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NOTA, legislators agreed that “it is against our system of values to auction 
off life to the highest bidder” and the buying and selling of “parts of human 
beings” is unacceptable.58 Then–veteran Representative Al Gore said that 
“Americans understand [that] . . . [t]hings are bought and sold. People are not, 
and parts of people shouldn’t be, either.”59 Gore, a champion and lead author 
of NOTA, took this a step further to suggest that allowing for the purchase 
and sale of organs from human beings would be contrary to the ideals 
supporting the abolition of slavery because “[we] don’t want to invest property 
rights in human beings.”60 Finally, Gore made an important distinction 
between organ donation and blood donation: “[T]he individual who donates 
blood suffers no harm”61 and suffers only minimal invasion. Additionally, the 
doctor who draws the blood “isn’t violating the Hippocratic oath.”62 
Applying this rationale to the context of 3D-printed organs leads to the 
opposite conclusion. To create a 3D-printed organ, a doctor need only inject 
a needle, much like that the process for drawing blood, to take a biopsy from 
the same person set to receive the printed organ. In that moment and 
thereafter, only one person must undergo an invasive procedure: the person 
who elected to receive his or her own printed organ. This is not a question of 
one person having the power to buy someone else’s life, but rather the idea 
that a patient may pay to use a part of his or her own body to, with the help of 
technology, heal. None of the ethical or human rights concerns associated with 
NOTA’s prohibition are present when organ transplants come from a printer. 
In sum, neither the plain text of NOTA nor its legislative history suggests 
that this law is meant to prohibit the introduction and use of 3D-printed 
organs to save lives in contemporary society. 
B. Market Rate Reimbursement is Not “Valuable Consideration” 
Even if manufactured organs were considered human organs, since they 
originated as human cells, the “valuable consideration” creating concern for 
lawmakers was explicitly not the reasonable costs associated with the transplant.63 
NOTA defines “valuable consideration” in the negative, as it expressly 
“does not include the reasonable payments associated with the removal, 
transportation, implantation, processing, preservation, quality control, and 
storage of a human organ or the expenses of travel, housing, and lost wages 
 
58 National Organ Transplant Act: Hearing on H.R. 4080 Before the Subcomm. on Energy and 
Commerce, 98th Cong. 128 (1983) [hereinafter Hearing on H.R. 4080] (statement of Rep. Gore). 
59 Id. at 112. 
60 Id. at 129. 
61 Id. 
62 Id. 
63 See discussion supra Section II.A. 
526 University of Pennsylvania Law Review [Vol. 166: 1 
incurred by the donor . . . in connection with the donation of the organ.”64 
Applied to the 3D-printed organ process, the corollary to “reasonable 
payments associated” would be reimbursement for the manufactured organ 
and the time spent by providers to transplant it. Likewise, the “expenses of 
. . . the donor” could be compared with the costs associated with collecting 
the cells through biopsy, printing onto the relevant scaffolding, and growing 
them into a transplantable organ, fit for human use. Any necessary 
preparatory medical attention required by the patient could rationally be 
covered by this section as well. 
While NOTA was being debated, experts in the field, such as the 
President of the American Society of Transplant Surgeons Dr. Oscar 
Salvatierra, Jr., expressed concern that individuals may “exploit people because 
they are in a desperate economic situation.”65 It was for this reason that the 
exchange of valuable consideration for human organs was proscribed. It was not 
to suggest that the operations at stake should be done at a loss or without the 
ability of those involved to recuperate their costs. In fact, disallowing 
reimbursement at a fair or “reasonable” market rate would go against the other 
principal aim of the bill, which was to “promote organ transplantation.”66 
The Ninth Circuit echoed this reasoning when it upheld the prohibition 
against paying for bone marrow in 2012, spending considerable time noting 
the “revolting” nature of commodifying physical parts of ourselves.67 
Plaintiffs in this case stipulated that their offer of $3,000 in the form of 
housing subsidies, scholarships or charitable donations to induce registration 
in their bone marrow donation network would be valuable consideration 
under NOTA,68 which has led some to believe that paying for 3D-printed 
organs would be similarly categorized, and therefore barred.69 I disagree. 
Providing market rate reimbursement for this procedure, the materials used 
to create the organ, and the related preparatory treatment for the patient is 
consistent with how the health care field operates. Providing incentives to 
encourage donation is completely distinguishable from compensating those 
who are engaged with the provision of health care services in the same way 
that they are compensated for every other procedure and treatment they 
perform. Furthermore, the issue of paying others for parts of their bodies for 
 
64 42 U.S.C. § 274e. 
65 Hearing on H.R. 4080, supra note 58, at 233. 
66 Supra note 56. 
67 Flynn v. Holder, 684 F.3d 852, 861 (9th Cir. 2012). 
68 See id. at 856 (noting the company’s concession that their payment mechanisms were 
valuable consideration). 
69 See Katherine A. Smith, “Transplanting” Organ Donors with Printers: The Legal and Ethical 
Implications of Manufacturing Organs, 49 AKRON L. REV. 739, 768 (2016) (concluding that Flynn’s reasoning 
“suggest[s] that no compensation of any kind could be given in exchange for a bioprinted organ”). 
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transplantation into someone else’s body is absent in the context of printed 
organs because the organ is grown and manufactured from cells of the person 
receiving the new organ. 
Accordingly, reasonable market rate reimbursement for the time and 
resources expended in an organ transplantation executed with a bioprinted organ 
would not constitute valuable consideration in the way proscribed by federal law. 
It would be preferable to preempt any potential litigation that may delay 
a life-saving operation by amending NOTA70 or a new round of notice and 
comment rulemaking by HHS to clarify the scope of their regulations 
promulgated pursuant to NOTA; however, neither of these must necessarily 
predate the introduction of 3D-printed organs into the market if one adopts 
the understanding of NOTA that I offer here. 
III. 3D-PRINTED ORGANS FIT IN THE EXISTING FRAMEWORK OF  
THE FEDERAL FOOD DRUG AND COSMETICS ACT  
AND CAN BE REGULATED BY THE FDA 
A. The FDA Is the Appropriate Agency to Regulate 3D-Printed Organs 
The FDA’s statutory mission is as simple as it is important: “to promote 
and protect the public health.”71 This explicitly applies to regulation of 
“cellular and tissue based products.”72 Accordingly, the FDA is the proper 
agency to vet, approve, and regulate these bioprinted organs once they are 
ready for human transplantation. 
The Federal Food, Drug and Cosmetic Act (FDCA) gives the FDA the 
“authority to monitor and regulate the safety of food, drugs and cosmetics.”73 
According to the available statutory definitions, 3D-printed organs could be 
regulated as drugs, medical devices, biologics, or any combination of the 
three, which could subject them to multiple sets of regulations. Manufactured 
organs fall within the ambit of FDCA governance, which will require greater 
consideration for the appropriate classification:74 “Determining whether a 
product is a drug, device, cosmetic, or biologic, or a combination of these 
components can often be tricky. The classification determination depends 
 
70 See Flynn, 684 F.3d at 862 (noting that “policy and philosophical choices are for Congress to 
make, not [the court]” in the context of finding rational basis for prohibiting compensation for the 
donation of human organs). 
71 U.S. FOOD & DRUG ADMIN., THE FUTURE OF DRUG SAFETY-PROMOTING AND 
PROTECTING THE HEALTH OF THE PUBLIC 17 (2007). 
72 See infra note 79 and accompanying text. 
73 21 U.S.C. §§ 301, 321, 331–99 (2012). 
74 See supra note 55 (discussing United States v. Regenerative Sciences, in which the D.C. Circuit 
upheld a determination that autologous stem cell procedures fall within the scope of intended 
FDCA regulation and constitute actions beyond just medical practice). 
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mainly on the intended use, mode of action, and ingredients.”75 I will explore 
this issue further later in this Section. 
B. 3D-Printed Organs Will Be Regulated Differently  
Than Human Organs for Transplantation 
Pursuant to Section 361 of the Public Health Service Act (PHS Act) and 
its corresponding regulations, the “FDA has implemented a risk-based 
approach to the regulation of HCT/Ps [human cellular and tissue based 
products].”76 The FDA has promulgated a list of requirements by which a 
product may qualify for an exception that subjects it only to regulation under 
Section 361 of the PHS Act.77 I have established that manufactured organs 
are, by their very nature, not “minimally manipulated,”78 but more 
importantly, the FDA has published guidance that includes a non-exhaustive 
list of what is not considered an HCT/P. In relevant part, it includes 
vascularized human organs, whole blood or blood components and extracted 
human products, including “cell factors.”79 Of course, the regulations cannot 
 
75 Renu Lal, Drug, Not a Drug, or More?, FDA/CDER SBIA CHRON. 1 (Sept. 17, 2015), 
https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/
UCM462854.pdf [https://perma.cc/DY89-ACGK]. 
76 U.S. FOOD AND DRUG ADMIN., HOMOLOGOUS USE OF HUMAN CELLS, TISSUES, AND 
CELLULAR AND TISSUE-BASED PRODUCTS: DRAFT GUIDANCE FOR INDUSTRY AND FDA STAFF 
2 (2015) [hereinafter HOMOLOGOUS USE]. 
77 Specifically: 
An HCT/P is regulated solely under section 361 of the PHS Act and [the regulations 
in this part] if it meets all of the following criteria: (1) The HCT/P is minimally 
manipulated; (2) The HCT/P is intended for homologous use only, as reflected by the 
labeling, advertising, or other indications of the manufacturer’s objective intent; 
(3) The manufacture of the HCT/P does not involve the combination of the cells or 
tissues with another article, except for water, crystalloids, or a sterilizing, preserving, 
or storage agent, provided that the addition of water, crystalloids, or the sterilizing, 
preserving, or storage agent does not raise new clinical safety concerns with respect to 
the HCT/P; and (4) Either: (i) The HCT/P does not have a systemic effect and is not 
dependent upon the metabolic activity of living cells for its primary function; or 
(ii) The HCT/P has a systemic effect or is dependent upon the metabolic activity of 
living cells for its primary function, and: (a) Is for autologous use; (b) Is for allogeneic 
use in a first-degree or second-degree blood relative; or (c) Is for reproductive use. 
21 C.F.R. § 1271.10 (2016). 
78 See supra note 54 (presenting the regulations’ definition of minimal manipulation); see also 
U.S. FOOD & DRUG ADMIN., MINIMAL MANIPULATION OF HUMAN CELLS, TISSUES, AND 
CELLULAR TISSUE-BASED PRODUCTS: DRAFT GUIDANCE FOR INDUSTRY AND FDA STAFF 2 
(2014) [hereinafter MINIMAL MANIPULATION] (providing guidance and examples of minimal 
manipulation and illustrating that 3D-printed organs would have both structural and non-structural 
tissues). 
79 HOMOLOGOUS USE, supra note 76, at 2; MINIMAL MANIPULATION, supra note 78, at 2; see 
also Paul Gadlock, HCT/P Regulation—351 vs 361 Products, ARENT FOX LLP (Feb. 15, 2017), 
http://www.pharmaconference.com/Attendee_Files-PDF/HCTP2_2017/13%20Gadiock%20-
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reflect a class of product that does not yet exist; however, it is easy to analogize 
to this list and conclude that 3D-printed organs would also not qualify for the 
exception. The guidance document states, 
If an HCT/P does not meet the criteria in 21 CFR 21 1271.10(a), and the 
establishment that manufactures the HCT/P does not qualify for any of the 
exceptions in 21 CFR 1271.15, the HCT/P will be regulated as a drug, device, 
and/or biological product under the [FDCA], and/or section 351 of the PHS 
Act, and applicable regulations, including 21 CFR Part 1271.80 
Therefore, 3D-printed organs will not be regulated as HCT/Ps. 
C. 3D-Printed Organs Should be Regulated as Biological Products 
Section 351(i) of the PHS Act defines a “biological product” as “a virus, 
therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or 
derivative, allergenic product, protein (except any chemically synthesized 
polypetide), or analogous product, . . . applicable to the prevention, treatment, 
or cure of a disease or condition of human beings.”81 Here, the key word is 
“protein:” the “bioink”82 used to manufacture these organs necessarily will 
contain human proteins required to grow the human organ for transplantation.83 
Biologics are typically “complex mixtures that are not easily identified or 
characterized.”84 It makes sense logically that part of our human biology would 
fall within the scope of biological product regulation and oversight. 
The classification also makes sense by analogy to chimeric antigen 
receptor T cell products, more commonly known as CAR-T therapies. For 
example, in March 2017, Novartis announced that the FDA accepted its 
Biologics License Application filing and granted priority review for one of its 
CAR-T products, which are “manufactured for each individual patient using 
 
%20HCTP%20351%20vs.%20361%20Products.pdf [https://perma.cc/8MTT-Q4FS] (listing cultured 
cartilage and nerve cells, gene therapy products, and human cells used in therapy involving the 
transfer of genetic material as examples of products that the FDA “determined do not meet all of 
the criteria in 21 C.F.R. 1271.10(a) and are regulated as drugs and/or biological products”). 
80 MINIMAL MANIPULATION, supra note 78, at 2-3. 
81 Regulation of Biological Products, 42 U.S.C. § 262(i)(1) (2016) (emphasis added). See infra 
Section IV.D for intended-use analysis. 
82 See supra notes 19–22 (discussing bioink). 
83 See Morber, supra note 21 (“For 3D bioprinting, scientists fill the ink cartridges with cells 
and proteins instead of plastic.”) (emphasis added); Janice R. Hermann, Protein and the Body, OKLA. 
COOPERATIVE EXTENSION SERVICE, http://pods.dasnr.okstate.edu/docushare/dsweb/Get/
Document-2473/T-3163web.pdf [https://perma.cc/2BG3-535Q] (noting that “body organs are all 
made from protein”). 
84 What are “Biologics” Questions and Answers, U.S. FOOD & DRUG ADMIN. (Aug. 5, 2015), 
https://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cber/ucm133077.htm 
[https://perma.cc/FCF3-ZDYS]. 
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their own T cells.”85 This treatment is being hailed as “‘a living drug’ that 
powerfully bolsters the immune system to shut down . . . disease.”86 Although 
it may be a less conventional setup for a combination product,87 these printed 
organs will very likely be subject to both biologic product regulations and 
drug regulations because “[biological] products subject to the PHS Act also 
meet the definition of drugs under the [FDCA].”88 
D. 3D-Printed Organs Should Also Be Regulated as Drugs 
In its relevant terms, the FDCA defines the term “drugs” as “articles 
intended for use in the diagnosis, cure, mitigation, treatment, or prevention 
of disease in man or other animals; and . . . articles (other than food) intended 
to affect the structure or any function of the body of man or other animals.”89 
This definition can be broken down into its two critical components: (1) 
intended use, and (2) effect on the structure and function of the body. 
While it does feel peculiar to characterize an organ as a drug, the 
manufactured organ’s intended use matches that of a drug. Under HHS 
regulations, promulgated pursuant to the authority delegated in the FDCA, 
intended use is the “‘objective intent’ of the persons legally responsible for 
the labeling of drugs. The intent is determined by such persons’ expressions 
or may be shown by the circumstances surrounding the distribution of the 
article.”90 The 3D bioprinting industry is not yet at the labeling, marketing, 
and distribution stages, so we cannot yet rely on these sources to inform the 
organs’ intended use. However, “[i]ntended use may also be established by 
consumer perception of a product’s reputation. In other words, why is the 
consumer buying the product and what does the consumer expect it to do?”91 
Even though 3D-printed organ development is in its nascent stages, we can 
answer this question based on decades of experience with human organ 
 
85 Novartis Announces First CAR-T Cell Therapy BLA for Pediatric and Young Adult Patients with 
r/r B-cell ALL Granted FDA Priority Review, NOVARTIS (Mar. 29, 2017), https://www.novartis.com/
news/media-releases/novartis-announces-first-car-t-cell-therapy-bla-pediatric-and-young-adult 
[https://perma.cc/UR9X-T9TL]. 
86 Denise Grady, F.D.A. Panel Recommends Approval for Gene-Altering Leukemia Treatment, N.Y. 
TIMES (July 12, 2017), https://www.nytimes.com/2017/07/12/health/fda-novartis-leukemia-gene-
medicine.html?mwrsm=Email&_r=0 [https://perma.cc/BNM2-G32X]. 
87 See generally Lal supra note 75, at 2 (generalizing that a product may be a combination product 
if it is “composed of any combination of a drug and a device; a biological product and a device; a 
drug and a biological product; or a drug, device, and a biological product”). 
88 Frequently Asked Questions About Therapeutic Biological Products, U.S. FOOD & DRUG ADMIN. (July 
7, 2015), https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/
approvalapplications/therapeuticbiologicapplications/ucm113522.htm [https://perma.cc/8SNQ-TB3J]; 
see also 42 U.S.C. § 262(j) (2012) (discussing the applicability of the FDCA to biological products). 
89 21 U.S.C. §§ 321(g)(1)(B)–(C) (2012). 
90 21 C.F.R. § 201.128 (2017). 
91 Lal, supra note 75, at 2. 
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transplants. Any patient seeking an organ transplant would almost necessarily 
be suffering from a medical ailment, whether it be a disease compromising 
the function of the organ to be transplanted, or a failure of the organ itself, 
such that it needs a replacement. Therefore, it is difficult to imagine a scenario 
in which someone would opt for an organ transplant for any reason other than 
cure, mitigation, treatment, or prevention of a disease or injury. 
This second point seems fairly self-evident, but it bears mentioning given 
the strict regulatory environment of the health care sector. Organs compose 
the core structure and function of our bodies; a replacement organ will 
continue to do so, whether it comes from a donor or the patient’s own cells 
that have undergone the additive manufacturing process. People seek organ 
transplants when their body is malfunctioning at its most basic level. The 
transplantation of a new, 3D-printed organ, would be intended to correct this 
malfunction and allow for improved internal bodily structure, which, in turn, 
would allow for better bodily functioning. 
E. 3D-Printed Organs Should Not Be Classified as Medical Devices 
The FDCA definition of medical “devices” shares the two provisions 
contained in the FDCA definition of drugs: (i) intended use and (ii) effect 
on the structure of function of the body.92 However, the statute specifically 
notes that a medical device is an “instrument, apparatus, implement, machine, 
contrivance, implant, in vitro reagent, or other similar or related article, 
including any component, part, or accessory,” which has the same intended 
use as drugs and biological products—or the same intended use as drugs and 
biological devices—but “does not achieve its primary intended purposes through 
chemical action within or on the body of man . . . and which is not dependent 
upon being metabolized for the achievement of its primary intended 
purposes.”93 Therefore, as the body functions by means of the chemical 
actions and reactions that occur within the organs, and a transplanted organ’s 
primary intended purpose would be to accomplish these actions more 
effectively than the organ it replaced, a 3D-printed organ falls outside the 
scope of this definition.94 
 
92 See supra text accompanying note 89 (defining the term “drugs”). 
93 21 U.S.C. § 321(h) (2012) (emphasis added). 
94 See JOSEPH JONES, MEDICAL AND SURGICAL MEMOIRS 136 (1876) (“[I]f the amount of 
blood circulating through any organ and the chemical actions are too great, how can they be regulated 
without some medium of communication, and some means of regulating the chemical and physical 
actions?”); JOHN GRAY MCKENDRICK, A TEXTBOOK OF PHYSIOLOGY: SPECIAL PHYSIOLOGY OF 
ORGANS 439 (1888) (“Chemical Actions.—As has been frequently pointed out, most of the 
operations occurring in the tissues involve chemical changes, principally those of oxidation.”). I 
would like to acknowledge and thank medical students Monica Gupta (Georgetown University) and 
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While some expect that the implanted nature of printed organs will lead 
the FDA to classify them as devices, the statutory language, and analogies to 
manufactured organs—which are currently regulated as devices—do not 
support this classification. In the FDA Product Classification Database for 
Devices, there are only fifty-six classifications of devices that qualify as 
implantable and life-supporting or sustaining.95 As one may expect from the 
list of descriptors in the statute, most of these devices are made of non-
bioabsorbable material (often metal).96 This is a distinguishing factor from 
the ink made of a person’s own biological material or cells in the manufactured 
organs. Furthermore, the non-metal implants may be absorbable, which is also 
unlike how an organ reacts to implantation.97 Rather, an organ functions as 
part of the body and with material directly from the body. Finally, perhaps 
one of the closest analogies that can be drawn is to replacement valves derived 
from donated cadaver or animal tissue.98 These valves are known as “more 
than minimally manipulated allograft[s],” which are intended for use in the 
“replacement of diseased, damaged, malformed, or malfunctioning native or 
prosthetic . . . valves.”99 This sounds analogous to the manufactured organ 
process and intended use; however, there is one critical difference. These 
valves were approved under the Humanitarian Device Exemption (HDE), 
which was created as a pathway for products “intended for diseases or 
conditions that affect small (rare) populations.”100 Pursuant to Section 3052 
 
Mike Kitchens (University of Pennsylvania) for the background they provided in this area and their 
confirmation that organs’ chemical actions are common knowledge in the relevant communities. 
95 Implanted Device Life Sustain/Support Device Search Results, U.S. FOOD & DRUG ADMIN., 
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm [https://perma.cc/KKD3-
WA3L]. 
96 See, e.g., Device: Synergy, NAT’L INST. HEALTH: NAT’L LIBR. MED., https://accessgudid.
nlm.nih.gov/devices/08714729840909 [https://perma.cc/R728-GDVJ] (describing the characteristics of 
a “sterile non-bioabsorbable metal tubular mesh structure covered with a non-bioabsorbable polymer 
and a drug coating that is designed to be implanted . . .” with FDA classification as a device). 
97 See, e.g., Product Classification for Absorbable Coronary Drug-Eluting Stent, FDA ACCESS DATA, 
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?ID=1049 [https://perma.
cc/VC54-SJHN] (describing an “absorbable scaffold with a drug coating placed via a delivery 
catheter . . . [that] [p]rovides mechanical support to the treated artery . . . and then gradually 
dissolves and is absorbed by the body” with FDA classification PNY (emphasis added)). 
98 See generally Heart Valve Replacement, ST. JUDE MED. (Nov. 7, 2016), 
https://www.sjm.com/en/patients/heart-valve-disease/treatment-options/heart-valve-replacement?
clset=af584191-45c9-4201-8740-5409f4cf8bdd%3ab20716c1-c2a6-4e4c-844b-d0dd6899eb3a [https://
perma.cc/6TYB-ERCH] (describing tissue heart valves that “are made from animal or human 
tissues . . . . Once the tissue is removed from the animal or human donor, it is chemically treated to 
preserve the tissue and prevent immunologic reactions after it is placed in a patient.”). 
99 Product Classification, U.S. FOOD & DRUG ADMIN. (Sept. 4, 2017), https://
www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?ID=1047 [https://perma.cc/
Q5UZ-8PNT]. 
100 Humanitarian Device Exemption, U.S. FOOD & DRUG ADMIN. (June 16, 2017), 
https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/Pre
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of the recently passed 21st Century Cures Act, a rare disease or condition is 
one that occurs in “not more than 8,000 individuals in the United States per 
year.”101 As the current waitlist for a donor organ is about 118,000 people long, 
bioprinted organs clearly do not qualify for this statutory exception.102 
In sum, even products that appear similar to products that the FDA has 
determined to be “devices” are distinguishable from 3D-printed organs in 
important ways. Additionally, as noted above in the discussion of the 
statutory language itself, no matter how similar these products are, they do 
not appear to achieve their primary intended purpose through chemical action 
within the body. The current statutory and regulatory language does not 
mandate the regulation of 3D-printed organs as medical devices. 
F. Bioprinted Organs Manufacturers Will Be Subject to Current Good 
Manufacturing Practices and Current Good Tissue Practices  
The FDA has taken great care to outline the minimum requirements with 
which drug and HCT/P manufacturers must comply. These are known as 
current Good Manufacturing Practices (cGMPs), which are applicable to the 
facilities that print the organs, and current Good Tissue Practices (cGTPs), 
which are applicable to the facilities that extract and handle the biopsied 
human cells.103 Failure to comply with cGMPs or cGTPs would result in the 
manufactured organ being classified as “adulterated,” which is a “prohibited 
act” under the FDCA.104 Furthermore, these regulations governing cGMPs 
and cGTPs are intended to complement each other to the fullest extent 
possible. If and only if there is a conflict between the regulations, “the 
regulation more specifically applicable to the [drug product or product] in 
question shall supersede the more general.”105 It remains to be seen which 
regulation the FDA will determine to be most “specifically applicable.” This 
 
marketSubmissions/HumanitarianDeviceExemption/default.htm [https://perma.cc/WBH6-HDBB] 
(citing § 3052 of the 21st Century Cures Act, Pub. L. No. 114-255). 
101 Id. 
102 See supra notes 10–12 and accompanying text (discussing the organ shortage in the United States). 
103 See Current Good Manufacturing Practice for Finished Pharmaceuticals, 21 C.F.R. § 211 
(2015) (outlining cGMPs for drugs); Biological Products: General, 21 C.F.R. § 600 (2012) 
(discussing cGMPs for biological products). 
104 See Status of Current Good Manufacturing Practices, 21 C.F.R. § 210.1(b) (2016) (“The 
failure to comply with any regulation set forth in this part . . . in the manufacture, processing, 
packing, or holding of a drug shall render such drug to be adulterated under . . . the act, and such 
drug . . . shall be subject to regulatory action.”); see also Adulterated Drugs and Devices, 21 U.S.C. 
§ 351 (2016) (outlining when a drug or device shall be deemed adulterated). 
105 21 C.F.R. § 211.1 (2016); see also Current Good Tissue Practice Requirements, 21 C.F.R. 
§ 1271.150(d) (2016) (“In the event that a regulation in part 1271 of this chapter is in conflict with a 
requirement in parts 210, 211, or 820 of this chapter, the regulations more specifically applicable to 
the product in question will supersede the more general.”). 
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determination is likely made based on the manufactured organs’ “primary 
mode of action.”106 
The first, second, and third enumerated “prohibited acts” in the FDCA 
refer to “adulterated” drugs, suggesting that preventing the introduction of 
adulterated drugs is a high priority for the FDA.107 It is important for drug 
producers to keep in mind that the smallest penalty for violating the FDCA’s 
prohibited acts is a misdemeanor.108 “Any person who violates a provision of 
section 331 of this title [the prohibited acts] shall be imprisoned for not more 
than one year or fined not more than $1,000, or both” for their first, non-
willful violation.109 The penalty increases significantly for willful violations 
(with the intent to defraud or mislead) or a violation subsequent to a prior 
conviction for committing a prohibited act.110 For the latter violations, a guilty 
person would be subject to up to three years in prison, a maximum fine of 
$10,000, or both.111 
The absence of an intent requirement in the first subpart of this penalties 
section gives the statute serious bite because it is, at a minimum, a strict 
liability misdemeanor. In other words, even an accidental violation of one 
cGMP could technically result in a misdemeanor conviction.112 In the case of 
intent or multiple violations, the violating party faces a felony charge. There 
are two important notes about these penalties. First, the penalties are not per 
person or per entity that violates the prohibited acts section of the FDCA. 
Rather, these penalties are assessed “per occurrence,” so the sum of the civil 
monetary penalties associated with convictions adds up quickly.113 
 
106 Frequently Asked Questions About Combination Products, U.S. FOOD & DRUG ADMIN. (Oct. 
20, 2016), https://www.fda.gov/combinationproducts/aboutcombinationproducts/ucm101496.htm 
[https://perma.cc/5LB9-74A5]; see also 21 C.F.R. § 3.2(m) (2017) (“Primary mode of action is the 
single mode of action of a combination product that provides the most important therapeutic action 
in the combination product . . . [which is] the mode of action expected to make the greatest 
contribution to the overall intended therapeutic effects of the combination product.”). 
107 Prohibited Acts, 21 U.S.C. §§ 331(a)–(c) (2012). The prohibited acts include: 
(a) [t]he introduction or delivery for introduction . . . of any . . . drug . . . that is 
adulterated or misbranded. (b) The adulteration or misbranding of any . . . drug (c) 
The receipt . . . of any . . . drug . . . that is adulterated or misbranded, and the delivery 
or proffered delivery thereof for pay or otherwise. 
Id. 
108 The penalties for violating the FDCA apply equally to the individuals and the entities 
through which they act. See Dictionary Act: Words denoting number, gender, and so forth, 1 U.S.C. 
§ 1 (2012) (clarifying that “the words ‘person’ and ‘whoever’ include corporations, companies, 
associations, firms, partnerships, societies, and joint stock companies, as well as individuals”). 
109 21 U.S.C. § 333(a)(1) (2013). 
110 § 333(a)(2). 
111 Id. 
112 Given prosecutorial discretion as well as the lack of government resources, the likelihood 
that the government would bring that case seems small. 
113 Amarin Pharma, Inc. v. U.S. Food & Drug Admin., 119 F.Supp. 3d 196, 203 (S.D.N.Y. 2015). 
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Second, and indisputably more important to all companies that provide 
any kind of health care service or product, is the threat of exclusion from 
government-sponsored health programs, such as Medicare and Medicaid. 
According to former Representative Allyson Schwartz, the government pays 
for approximately fifty percent of health care in this country,114 so exclusion 
from these government-funded programs would be seriously damaging to 
companies involved in the health care sector. The Office of the Inspector 
General “has the authority to exclude individuals and entities from [f]ederally 
funded health care programs,” pursuant to the Social Security Act.115 The 
statutory minimums vary depending on the nature and amount of the offenses. 
In addition to the many, meticulously detailed requirements for cGMPs, 
creators of 3D-printed organs will also likely be subject to current Good 
Tissue Practices (cGTP),116 because the organs are “tissue-based 
product[s].”117 Establishments that manufacture tissue-based products “that 
are regulated as drugs, devices, and/or biological products” under the FDCA 
are required to “register and list” their tissue-based products following the 
procedures promulgated under 21 C.F.R. § 207, regulating the registration 
and listing of human drugs.118 
An important subpart of cGTPs is the Donor Eligibility Requirements.119 
However, as the tissue used to grow the new, manufactured organ would be 
both biopsied from and received by the same individual, 3D-printed organs 
would fall in the specific “Autologous Use” exception to these regulations. 120 
Accordingly, they will not be subject to the rigorous testing requirements 
meant to protect against the spread of communicable disease. This is a 
rational and efficient carveout by the FDA, because testing someone’s tissue 
before reinserting it into his or her own body would, of course, not serve the 
purpose of preventing the spread of disease. Thus, the only relevant 
requirements from this subsection regarding donor eligibility would be those 
 
114 Allyson Schwartz, CEO of the Better Medicare Alliance; Former Member of the House of 
Representatives, Panelist at the Wharton Public Policy Initiative Talk about The Future of American 
Health Care (May 1, 2017). 
115 Exclusions: Background Information, OFF. INSPECTOR GENERAL, https://oig.hhs.gov/
exclusions/background.asp [https://perma.cc/UJD8-RJ8Y] (explaining OIG exclusion authority and 
discretion). 
116 Current Good Tissue Practice, 21 C.F.R. §§ 1271.145–320 (2017) (describing the elements of 
current good tissue practice). 
117 Applicability of Current Good Manufacturing Practice Regulations, 21 C.F.R. § 210.2(a) (2017). 
118 Human Cells, Tissues, and Cellular and Tissue-Based Products, 21 C.F.R. § 1271 (2017). 
119 See generally 21 C.F.R. §§ 1271.45–90 (2017) (describing donor eligibility requirements under 
cGTPs). 
120 See Are There Other Exceptions and What Labeling Requirements Apply? 21 C.F.R. § 
1271.90(a) (2016) (clarifying that there is no requirement to make a donor-eligibility determination 
or perform donor screening/testing when the relevant “cells and tissues” are “for autologous 
[involving one individual as both donor and recipient] use”). 
536 University of Pennsylvania Law Review [Vol. 166: 1 
governing labeling to ensure the person gets the organ grown from his or her 
own cells.121 
Technically, according to the defined scope of this chapter of federal 
regulations, certain regulations apply to human tissue used for 
transplantation and to establishments or individuals involved in the 
“screening, testing, processing, storage, or distribution” of such.122 However, 
tissue, herein referred to as “human tissue,” is defined as 
any tissue derived from a human body and recovered before May 25, 2005, 
which: (1) [i]s intended for transplantation to another human . . .; (2) [i]s 
recovered, processed, stored, or distributed by methods that do not change 
the tissue function or characteristics; (3) [i]s not currently regulated as a 
human drug, biological product, or medical device; (4) [e]xcludes . . . 
vascularized human organ[s] . . . .123 
3D-printed organs do not fit this definition and therefore fall outside of 
its scope. 
As with all FDA-regulated bodies, manufacturers of tissue-based products 
must allow for FDA inspection at the agency’s discretion.124 In reality, it is 
rare for a facility to come out of an inspection without any observations that 
require remediation,125 and consequences of an FDCA violation can vary. 
However, these penalties can be quite significant, and can go so far as to 
immediately shut down manufacturing.126 This would render the 3D printing 
of any organs in queue incomplete until further notice, which could have 
major, life-altering or ending consequences for the patients who await these 
transplants and/or serve as the death knell for the additive manufacturing 
company at issue. However, holding these companies to the FDA’s rigorous 
 
121 See § 1271.90(c) (“As applicable, you must prominently label a [tissue-based product] . . . as 
follows: (1) FOR AUTOLOGOUS USE ONLY, if it is stored for autologous use. (2) NOT 
EVALUATED FOR INFECTIOUS SUBSTANCES, unless you have performed all otherwise 
applicable screening and testing . . . .” (internal quotation marks omitted)). 
122 Human Tissue Intended for Transplantation, 21 C.F.R. § 1270.1(a) (2017). 
123 Id. at 792 (emphasis added). 
124 Inspections, 21 C.F.R. § 1271.400 (2017) (explaining that the FDA possesses total discretion 
in the time, manner, and frequency of inspections of manufacturer facilities, and further that the 
FDA’s respresentatives “may use other appropriate means to record evidence of observations during 
inspections”). 
125 See, e.g., Warning Letter from Marisa Heayn, Consumer Safety Officer, U.S. Food & Drug 
Admin. to Roger J. Hinton, Managing Dir., Porton Biopharma Ltd. (Jan. 19, 2017), https://www.fda.
gov/iceci/enforcementactions/warningletters/2017/ucm538105.htm [https://perma.cc/N25W-5ADN] 
(listing several violations after inspecting Porton Biopharma’s drug manufacturing facility). 
126 See Orders of Retention, Recall, Destruction, and Cessation of Manufacturing, 21 C.F.R. 
§ 1271.440(a)(3) (2017) (describing that the FDA’s most severe penalty for noncompliance with 
cGTPs is “an order to cease manufacturing until compliance with the regulations of this part has 
been achieved. When FDA determines there are reasonable grounds to believe there is a danger to 
health, such order will be effective immediately . . . .”). 
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benchmarks is appropriate in the context of printing something as critical as 
an entire organ because any lower standard could present extraordinary 
danger or further complications for the patients who need these transplants. 
IV. ETHICAL CONSIDERATIONS FOR TRANSPLANTING  
3D-PRINTED ORGANS 
Accepting my proposition that 3D-printed organs are well on their way, 
and that the existing legal and regulatory framework has the tools to make 
itself ready for their arrival, we are left to question the ethical permissibility 
of using these manufactured organs for transplantation into humans, while 
lacking significant safety and efficacy data. The consideration of ethical 
challenges presented by transplantation of 3D-printed organs raises more 
questions than answers at this point in the technology’s development and is 
a vast area, worthy of its own Comment; however, there are a few aspects of 
manufactured organs to which researchers and health care providers ought to 
pay careful attention as these organs evolve from new, experimental products 
to a more commonplace set of treatment options. I raise them here for further 
consideration. 
A. There is No Applicable Constitutional Right to Access  
Unapproved 3D-Printed Organs 
Pursuant to the famous Abigail Alliance case, there is no constitutional 
right to access unapproved drugs.127 According to the D.C. Circuit, this right 
was neither fundamental nor deeply rooted in the nation’s history and 
traditions (using the Glucksberg standard),128 but I challenge others interested 
in this field to consider whether organ transplantation is distinguishable, due 
to the longer history of organ transplantation in this country. Congress may 
be trying to pass legislation to provide greater access to experimental 
treatments for the terminally ill, as many states have,129 but some are dubious 
that this is the proper solution to help this population.130 Perhaps the FDA 
 
127 Abigail All. for Better Access to Developmental Drugs v. von Eschenbach, 495 F.3d 695, 
711 (D.C. Cir. 2007) (en banc). 
128 Hyman, Phelps & McNamara, P.C., D.C. Circuit Court Rules in Abigail Alliance Case; Affirms 
District Court Ruling That There is No Fundamental Right of Access to Experimental Drugs for the 
Terminally Ill, FDA LAW BLOG (Aug. 7, 2007, 1:41 PM), http://www.fdalawblog.net/fda_law_
blog_hyman_phelps/2007/08/dc-circuit-cour.html [https://perma.cc/J84G-5B6T]. 
129 See Ohio Becomes 33rd State to Adopt Right to Try Law for Terminally Ill, GOLDWATER INST. 
(Jan. 5, 2017), http://www.goldwaterinstitute.org/en/work/topics/healthcare/right-to-try/ohio-
becomes-33rd-state-to-adopt-right-to-try-law-/ [https://perma.cc/2E9C-QM5J] (reporting that 
thirty-three states have passed right-to-try laws). 
130 See generally Alison Bateman-House, Kelly McBride Folkers, & Arthur Caplan, ‘Right to Try’ 
Won’t Give Patients Access to Experimental Drugs. Here’s What Will HEALTH AFF. BLOG (May 3, 2017), 
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will allow 3D-printed organs to enter the market through the Expanded 
Access for Investigational New Drug (IND) pathway131 or another exception, 
but this would likely require updates or amendments to the current 
frameworks. How to do this well, let alone most effectively, is a topic for 
further research. What is clear is that placebo-controlled clinical trials are 
clearly not ethically permissible because they would involve withholding 
organ transplants from those who need them or subjecting perfectly healthy 
people to risky organ transplants that they do not need. Additionally, animal 
trials are already underway;132 but it remains to be seen whether the FDA will 
accept data from these investigations. What the FDA may allow is 
comparative studies. For kidneys, this may mean comparing human organ 
transplantation with manufactured organ transplantation or even comparing 
dialysis treatment with manufactured organ transplantation. Additionally, 
such a comparative study would require the Agency to approve a trial that, by 
design, cannot be blinded because of the differing timing, processes, and 
treatments associated with each of the procedures. 
Despite the uncertainty, there is historical evidence that when a 
population has no other option, risk tolerance in the absence of safety and 
effectiveness data is higher than in any other situation, and the FDA may be 
willing to develop new frameworks to support introduction of a lifesaving 
treatment. For example, during the Ebola epidemic, World Health 
Organization (WHO) experts concluded “that it was ethical to offer non-
registered experimental interventions to Ebola patients, conditional on the 
collection of evidence to inform the broader community on their efficacy.”133 
Just because diseases affecting organ function or failure are not typically 
 
http://healthaffairs.org/blog/2017/05/03/right-to-try-wont-give-patients-access-to-experimental-
drugs-heres-what-will/ [https://perma.cc/NDK7-PMUX] (explaining why right to try laws will not 
increase access to experimental drugs and exploring other potential avenues through which that goal 
might be achieved). 
131 See generally Expanded Access to Investigational Drugs for Treatment Use, 74 Fed. Reg. 
40,900 (Aug. 13, 2009) (clarifying the 1987 regulations that expanded access to investigational, new 
drugs for treatment). 
132 See, e.g., Serenitie Wang & Katie Hunt, Chinese Company Implants 3-D Printed Blood Vessels 
into Monkeys, CNN (Jan. 10, 2017), http://www.cnn.com/2017/01/10/health/china-3d-printed-blood-
vessels/ [https://perma.cc/E6BP-D5SW] (“Chinese scientists working for Sichuan Revotek have 
successfully 3-D printed blood vessels and implanted them in rhesus monkeys . . . . It is a major step 
on the road to mass printing human organs for transplants.”). 
133 Compassionate Use of Experimental Treatments for Ebola Virus Disease: Outcomes in 14 Patients 
Admitted from August to November, 2014, WORLD HEALTH ORG., http://www.who.int/
medicines/ebola-treatment/outcomes_experimental_therapies/en/ [https://perma.cc/CYC7-5GF6]; 
see also infra note 135 (discussing the new frameworks developed by the WHO in order to support 
the introduction of a lifesaving treatment for Ebola). 
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infectious does not mean the situation here is any less urgent, as evidenced 
by the organ transplant waiting lists.134 
B. Perhaps Money Can Buy Organs 
With every emerging technology, it is almost always those with the most 
financial resources and influence that learn about new developments first and 
have access before everyone else.135 3D-printed organs will likely be no 
exception. Given the high-tech nature of the process, news of its arrival is 
likely to start at the top for those with the greatest access to industry 
developments and with the highest levels of education and resources. 
Accordingly, the first patients in the door asking to have a manufactured 
replacement organ will be those who have been informed that the possibility 
exists. Of course, this uneven access poses ethical problems because there are 
fairer ways to determine who gets the first manufactured organs than by 
wealth, industry access, or education level. 
The FDA response in its final rule regarding Expanded Access to 
Investigational Drugs for Treatment and Use addressed the issue of access in 
two important ways. First, it noted the likelihood that demand will exceed 
supply of these investigational drugs and that access determinations “should 
be as equitable as reasonably possible.”136 Rather than attempt to set standards 
to apply to all INDs, the FDA took the pragmatic approach to allow these 
analyses to be done on a “case specific” basis.137 As part of this process, “[the] 
FDA believes it is advisable” to undertake consultation with “relevant patient 
or disease advocacy organizations, professional societies, and other affected 
constituencies to devise the most appropriate mechanism for allocating a 
limited drug supply in a specific situation.”138 In this case, the Organ 
Procurement and Transplantation Network, a “public–private partnership that 
links all professionals involved in the U.S. donation and transplantation 
 
134 See supra notes 9–11 and accompanying text (discussing organ waitlists and the organ 
shortage). 
135 See Adrienne LaFrance, Technology, the Faux Equalizer, ATLANTIC (Mar. 31, 2016), 
https://www.theatlantic.com/technology/archive/2016/03/half-full-tech/476025/ [https://perma.cc/
7VE9-SW4M] (“New technologies are for the elite who can afford them” (quoting Judith Donath, 
author of THE SOCIAL MACHINE: DESIGNS FOR LIVING ONLINE)); see also Susan Donaldson James, 
Who Gets Ebola Drugs? AIDS, Dialysis and Cancer ‘Cures’ Point the Way, NBC NEWS (Aug. 19, 2014), 
http://www.nbcnews.com/storyline/ebola-virus-outbreak/who-gets-ebola-drugs-aids-dialysis-cancer-
cures-point-way-n181891 [https://perma.cc/G8U7-HKZW] (raising ethical questions about the 
distribution of Ebola drugs).  
136 74 Fed. Reg. 40,904 (Aug. 13, 2009). 
137 Id. 
138 Id. at 40,905. 
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system,” established by NOTA, should be involved.139 These members have the 
most experience managing organ waitlists and prioritization among very sick 
and vulnerable groups of people and have already developed thoughtful and 
robust systems to determine how best to allocate organs and in what order.140 
The ethical challenges associated with what factors one can permissibly include 
in these calculations are endless, and they should be left to those with the most 
expertise and the least susceptibility to bias in the process. 
Second, the FDA acknowledges the reality that, with the “investigational” 
label, insurance companies are unlikely to pay for these transplantations, 
despite the agency’s hope that the companies “make well-reasoned 
reimbursement decisions that will not impinge on the availability of 
investigational drugs for treatment use.”141 Unfortunately, the FDA “has no 
inherent authority to dictate” any requirements for insurance and other third 
party payers’ reimbursement policies.142 The predictable consequence is that, 
if insurance companies decide not to reimburse for manufactured organ 
transplants, access would likely be foreclosed for “some patients (e.g., those 
who lack the financial resources to pay out-of-pocket).”143 
As such, perhaps financial resources and the access they provide will be 
inescapable factors in determining who gets the first 3D-printed organs, and 
ultimately which populations will have the most lives saved by this new 
technology, despite the fact that experts in the field have developed fairer 
ways to allocate such precious resources. Eventually, the issue presented by 
greater demand than supply of printers to manufacture new organs will fade 
as the printing process gets faster and more printers are made available, but 
this challenge merits considerable attention and every possible safeguard in 
the meantime. The FDA subtly tipped its hand regarding its views on this 
matter in their responses to comments about the proposed rule. It explicitly 
took “no position on how the terms ‘reasonable,’ ‘necessary,’ or ‘medically 
necessary’ in health insurance contracts should be interpreted” for INDs.144 
In other words, the FDA seems to be challenging the insurers to come out in 
favor of coverage for these INDs when they are “necessary,” even though they 
are technically still investigational. 
 
139 About the Organ Procurement and Transplantation Network (OPTN), U.S. DEP’T OF HEALTH 
& HUM. SERVS., https://optn.transplant.hrsa.gov/governance/about-the-optn/ [https://perma.cc/
U4XH-55G6]. 
140 See, e.g., Organ Procurement and Transplantation Network Allocation Calculators, U.S. DEP’T 
OF HEALTH & HUM. SERVS., https://optn.transplant.hrsa.gov/resources/allocation-calculators/ 
[https://perma.cc/P4TT-XKWX] (providing access to and explanation of the formulas used to 
determine appropriate allocations of donated organs to those on the transplant waiting lists). 
141 74 Fed. Reg. 40,907 (Aug. 13, 2009). 
142 Id. 
143 Id. 
144 Id. 
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C. Will Insurers Ever Cover a Procedure to Keep Sick Beneficiaries Alive Longer? 
While insurers have long refused to cover treatments that have yet to be 
fully approved by the FDA,145 it is unclear whether they will, without legal 
requirement, decide to cover 3D-printed organs even after they have achieved 
full approval. Those who will seek bioprinted organs will be extremely sick. 
From the insurers’ perspective, this is their most expensive population, and, 
economically speaking, it is better for business when these people pass away 
because continuing to finance their treatment can be incredibly expensive.146 
With these two data points, it seems directly averse to insurers’ financial 
interests to substantially extend a very sick beneficiary’s life by covering a 
bioprinted organ. Hopefully the legislative framework will not lag too far 
behind the technological advances in this field, such that 3D-printed organs 
will rise to become the standard of care or necessary, lifesaving treatments that 
insurers will have no choice but to include on their formularies. 
One initial exception to this financial disincentive might be kidneys for 
dialysis patients: “economist Mark Schnitzler and transplant surgeon Arthur 
Matas estimated that each kidney transplant saves society $90,000” because “a 
transplant costs far less than keeping a patient on dialysis.”147 Therefore, financial 
and humane incentives align in this circumstance. Fortunately, kidneys will likely 
be the first bioprinted organs to market because they are slightly lower risk (we 
only need one to survive) and the demand created by dialysis patients is already 
significant.148 Perhaps the precedent set by kidneys will alleviate the need to take 
up this fight with insurance companies and other payers. 
D. [Un]Informed Consent 
Informed consent is one of the most important facets of any 
investigational study or clinical trial because those subjecting themselves to 
the risks involved must do so knowingly. In the context of IND expanded 
 
145 See Rachel Sachs, Your Weekly Reminder That Approval and Insurance Coverage Are Often 
Linked, BILL OF HEALTH: HARV. L. (Nov. 30, 2016), http://blogs.harvard.edu/billofhealth/
2016/11/30/your-weekly-reminder-that-fda-approval-and-insurance-coverage-are-often-linked/ 
[https://perma.cc/Q2H5-9T8M] (“FDA approval is often linked to insurance coverage. Medicaid 
must cover essentially all FDA-approved drugs, and Medicare similarly has limited ability to decline 
to cover FDA-approved drugs.”). 
146 See generally Sandra G. Boodman, Costliest 1 Percent of Patients Account For 21 Percent Of U.S. 
Health Spending, KAISER HEALTH NEWS (Oct. 7, 2013), http://khn.org/news/one-percent-of-
costliest-patients/ [https://perma.cc/3MMS-7KNT] (analyzing how a small group of the sickest 
people can cost the most in health care dollars). 
147 Annie Lowrey, The Kidney Trade: Can Economists Make the System for Organ Transplants More 
Humane and Efficient?, SLATE (Dec. 15, 2010), http://www.slate.com/articles/business/moneybox/
2010/12/the_kidney_trade.html [https://perma.cc/M9LH-Z3ZP]. 
148 See A Tissue of Truths, supra note 9 (identifying one medical-technology company that predicts 
3D-printed kidneys will be possible in six years). 
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access and manufactured organ transplantations for those facing death or 
serious illness, the populations in question are “particularly vulnerable.”149 
Accordingly, the FDA recommends “a rigorous informed consent process” 
and “encourages submission of informed consent documents intended to be 
used” for the FDA’s feedback in these situations.150 The FDA rejected 
commenters’ requests to “add specific informed consent requirements to the 
expanded access regulations” because the informed consent rules under its 
robust Protection of Human Subjects regulations provide the necessary 
guidance and safeguards as they are.151 Despite the FDA’s confidence in the 
existing regulations for informed consent, it is unclear whether we can call 
consent in this area truly informed. This technology is nothing short of 
revolutionary, and it is difficult to find an apt analogy. 
Therefore, as all of the risks are not yet known, it is quite impossible for 
sponsors of trials or providers of the bioprinted organs to provide a complete 
picture of the risks and benefits of participation in these early stages. Each 
person will present a unique case, and no two printed organs or procedures will 
be exactly alike. Given the greater potential benefits than risks for populations 
that are facing almost certain death without intervention, I believe it is ethically 
permissible to allow this imperfect consent at the earliest stages if, and only if, 
sponsors are clear that there is uncertainty in brand new technology and the 
participants accept this price of their involvement. Relatedly, the importance 
of not creating unrealistic optimism or unfounded hope for the first round of 
bioprinted organ transplants cannot be overstated.152 
E. 3D-Printed Organs Could Put Black Markets (For Organs) Out of Business 
While this final ethical consideration is outside the scope of U.S. 
regulations, it is equally worthy of our attention. The organ shortage has led 
to deaths on both sides of the equation. The visible suffering we see from 
people and their families who run out of time before being matched with a 
suitable organ is heartbreaking, to be sure, but their tragedies are due to 
systemic failures to provide enough organs to meet the demand. It is difficult 
to point fingers at any party as blameworthy. This is not the case for the other 
“invisible” group of victims of the organ shortage. We cannot just blame the 
 
149 74 Fed. Reg. 40,920 (Aug. 13, 2009). 
150 Id. 
151 Id.; see also Informed Consent of Human Subjects, 21 C.F.R. §§ 50.20–27 (2016) (detailing 
the requirements and exceptions to informed consent); Institutional Review Boards, 21 C.F.R. 
§§ 56.101–24 (2016) (detailing the informed consent requirements for investigations involving 
human subjects and the Institutional Review Board (IRB) oversight thereof). 
152 See supra note 139, at 40,920 (noting the importance of “effectively communicat[ing] . . . in 
a way that does not raise false expectations about a positive outcome from treatment and makes clear 
what is unknown about the drug”). 
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system for their pain and suffering. Rather, the responsible parties are 
members of worldwide organ trafficking rings who murder people and sell 
their organs for enormous profits. The ethical reprehensibility of their actions 
is immeasurable, but, unfortunately, business is booming. 
Selling organs is illegal in every country except Iran, but it still happens; 
the WHO estimates, for example, that one in five kidney transplants is done 
with an organ bought on the black market.153 For instance, a South African 
hospital “admitted taking about $500,000 from an organ trafficking 
syndicate.”154 In Brazil and Romania, kidneys (including those harvested from 
children) can be sold for $6,000 each.155 To put that in perspective, this single 
transaction pays approximately ten times what the average Brazilian156 or 
Romanian157 makes in a whole month. Notwithstanding the question of 
whether such large amounts of money are per se coercive, one could argue that 
individuals should be able to part with an unneeded organ for financial reasons, 
but organ trafficking extends far beyond personal choice. In the more extreme, 
but not uncommon, circumstances, people are kidnapped and killed by organ 
trafficking rings, and their bodies are gutted to allow for transplantation of 
all of their organs into others.158 Sometimes these rings are operated by shady, 
back alley gangs, but other times those in the high positions of government 
may allegedly be behind these deals.159 According to a Boston-based attorney 
who has experience with the development of 3D printing, the large-scale 
availability of organs once bioprinting becomes commonplace could be a 
powerful tool to undermine the organ trafficking black market and shield 
 
153 Lowrey, supra note 147. 
154 Id. 
155 Id. 
156 See In Booming Brazil, Census Shows Income Gap Persists, WORLDCRUNCH, (Nov. 20, 2011) 
https://www.worldcrunch.com/business-finance/in-booming-brazil-census-shows-income-gap-
persists [https://perma.cc/JD7P-FS4L] (citing the average monthly income in Brazil as $678.90). 
157 See Comunicat Castig Salarial, NAT’L INST. STAT. (Nov. 6, 2015), http://www.insse.ro/
cms/en/tags/comunicat-castig-salarial [https://perma.cc/3US6-22QD] (noting the average gross 
nominal monthly income in Romania as 2,541 lei). At the time, one lei was worth about $0.24, 
converting to an average monthly income of $612. XE Currency Table: RON–Romanian Leu, XE (Nov. 
6, 2015), http://wwww.xe.com/currencytables/?from=RON&date=2015-11-06 [https://perma.cc/
HQ2UHX2E]. 
158 See Paul Lewis, Kosovo PM is Head of Human Organ and Arms Ring, Council of Europe Reports, 
GUARDIAN (Dec. 14, 2010), https://www.theguardian.com/world/2010/dec/14/kosovo-prime-
minister-llike-mafia-boss [https://perma.cc/E5PC-YP2C] (“As and when the transplant surgeons 
were confirmed to be in position and ready to operate, the captives were brought out of their ‘safe 
house’ individually, summarily executed by a [Kosovo Liberation Army] gunman, and their corpses 
transported swiftly to the operating clinic.”). 
159 See id. (discussing a report alleging that the former prime minister of Kosovo was “the head 
of a ‘mafia-like’ Albanian group responsible for smuggling . . . human organs through eastern 
Europe”). 
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more of the world’s most common victims from these atrocities.160 This would 
be an enormous victory for international human rights. 
CONCLUSION 
There is no question that the FDA’s regulation of products that affect our 
daily lives is complicated. 3D printing technology breaks new ground every day, 
and the Agency’s existing regulatory framework certainly did not contemplate 
such a revolutionary and “disruptive” market shift, to provide adequate 
regulation and oversight. On the one hand, we want those whose very survival 
depends on an organ transplant to have access to bioprinting technology as soon 
as possible; on the other hand, we must ensure that its introduction to market 
is coupled with adequate oversight and safeguards.161 
Many predict that kidneys will be the first 3D-printed organs to market 
for two reasons. First, kidney transplantation poses a lower risk because 
people need only one functioning kidney to survive. Second, renal failure is 
associated with a myriad of complicated and expensive conditions. Federal 
lawmakers have grappled with the complexities associated with organ 
transplantation for decades, but the concerns addressed in the National Organ 
Transplant Act (NOTA) are beyond the scope of the unique challenges of 
manufactured organs. Therefore, when these kidneys are ready, it will not be 
a federal crime to manufacture, sell and transplant them under NOTA. The 
FDA will dually regulate them as biological products and drugs, as their 
intended use will be to cure, mitigate, treat, or prevent the patient’s ailment 
through their direct effect on the structure and function of his or her body. 
The proteins in these kidneys will achieve their primary intended purpose of 
substituting for dialysis or providing healthy organ function through the 
chemical action with the rest of the human body. As with any biological 
product and drug, the manufacturing, labeling, and transportation of these 
kidneys must comply with all applicable current Good Manufacturing and 
Tissue Practices, pursuant to the FDA’s regulations under the Federal Food, 
Drug, and Cosmetic Act and the Public Health Services Act. However, the 
questions that must be answered first are: Which patients will be at the front 
of the line to receive the treatment? Which should be? 
There is very little about 3D-printed organs that is intuitive, and its 
regulation will be equally complex. Nevertheless, the framework to support 
3D printing exists, and the FDA need not hesitate to welcome these organs 
into the health care market. Bioprinting promises to revolutionize the 
 
160 Interview with Anonymous Source (May 2, 2017). 
161 See Miller, supra note 55, at 437 (“New medical technologies are constantly pushing the 
regulatory envelope, creating new agency challenges for effective oversight.”). 
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practice of medicine through the eventual eradication of organ shortage and 
transplant rejection problems. A careful assessment of ethical challenges 
posed by 3D-printed organs will remain critical as the technology becomes 
available for human transplantation. As other countries, such as China,162 
move closer to human transplantation, the richest cohorts of the United 
States will be able to travel to receive these 3D-printed organs even if they 
cannot access them at home. We must develop means to ethically bring this 
technology to American hospitals. 
President Theodore Roosevelt rightly said, “Nothing in this world is 
worth having or worth doing unless it means effort, pain, [and] difficulty.”163 
Arriving at the day when no one dies for want of an organ transplant is 
certainly worth doing, and the world must brace itself to invest the requisite 
effort and resources to face the difficult challenges ahead. The end result is 
too important to choose any other course. 
 
 
162 See supra note 132. 
163 President Theodore Roosevelt, Address at the Iowa State Teachers’ Association (Nov. 4, 
1910). 
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